Page contentsKey factsDecisionKey facts Active Substance Gefapixant (citrate salt) Therapeutic area Endocrinology-Gynaecology-Fertility-Metabolism Decision number P/0100/2020 PIP number EMEA-002267-PIP03-19 Pharmaceutical form(s) Film-coated tablet Condition(s) / indication(s) Treatment of endometriosis Route(s) of administration Oral use Contact for public enquiries Merck, Sharp & Dohme (Europe) Inc.Tel. +33 180464738E-mail: pip.information@merck.com Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 18/03/2020DecisionP/0100/2020: EMA decision of 18 March 2020 on the granting of a product specific waiver for gefapixant (citrate salt) (EMEA-002267-PIP03-19)AdoptedReference Number: EMA/76893/2020 English (EN) (225.11 KB - PDF)First published: 28/07/2020ViewShare this page